Published on : Jan 10, 2017
ALBANY, NY, Jan 10, 2017: Hypertension, a chronic medical condition in which the arterial blood pressure increases to or over 140/90mm Hg, afflicts mostly the elderly. As per the National Stroke Association (NSA), around two-thirds stroke patients have hypertension. Hypertension itself does not exhibit any symptoms, but can damage different organs due to the high blood pressure. It can be thwarted by medical treatment or by incorporating changes in the lifestyle. In fact, deaths resulting from hypertension can be prevented to a great extent with timely diagnosis and therapeutics.
A newly added research report discusses the scope of the anti-hypertensive therapeutics market in Asia Pacific. The report, titled “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline,” finds that the Asia-Pacific antihypertensive therapeutics market would attain a value of US$27 bn in 2022 from $19.1 billion in 2015, clocking a 5.1% CAGR.
The report pegs a burgeoning geriatric population, rising daily sodium intake, growing instances of obesity and overweight issues, an increase in sedentary lifestyle, growing number of smokers and rising consumption of alcohol, and a range of healthcare reforms as primary market stimulants in the region. It finds the weak pipeline of drugs, high uptake of generic drugs, non-pharmacological first-line treatment, and low awareness about hypertension among the people and physicians to be major market dampers.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=903617
The reports furnishes information on the gamut of anti-hypertensive treatment options available in the market these days. Those include angiotensin receptor blockers, angiotensin converting enzyme inhibitors, beta blockers, calcium channel blockers, diuretics, and renin inhibitors. They can be used as monotherapy or as combination therapy. The report uncovers that the market for anti-hypertensive therapeutics in Asia Pacific is dominated mainly by generics and that there are just a handful of patented products. It attempts to gauge the future prospects of generics in the market and also analyzes the likely impact of patent expirations of the current branded therapies on the market.
The report finds the present anti-hypertensive therapeutics pipeline to be weak, with 112 molecules in different development phases. The pipeline mostly comprises of small molecules. The report further delves into the clinical trial procedures to provide information about them. The information includes the failure rate by phase and molecule type, duration by molecule type and molecular target, and the size of the trials.
The report also segments the Asia Pacific market for anti-hypertensive therapeutics based on geography into India, China, Australia, South Korea, and Japan. It provides an assessment of the market in each of the countries vis-à-vis size, sales and revenues, and growth prospects. It forecasts Japan to contribute majorly to the Asia Pacific market on account of the steep cost of therapy annually.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org